AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It ...

AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Investors were reassured after the drugmaker said a potential fine in China would have only a minor business impact.The ...

AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.

The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...